Diametric Capital LP Lowers Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

Diametric Capital LP decreased its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 22.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 223,770 shares of the company’s stock after selling 63,489 shares during the period. Diametric Capital LP owned about 0.10% of Gossamer Bio worth $202,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. The Manufacturers Life Insurance Company lifted its stake in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after acquiring an additional 74,920 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Gossamer Bio by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock valued at $1,123,000 after purchasing an additional 13,902 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Gossamer Bio by 30.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock valued at $1,862,000 after purchasing an additional 442,895 shares in the last quarter. Finally, Monaco Asset Management SAM grew its position in Gossamer Bio by 39.5% in the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.

Wall Street Analyst Weigh In

GOSS has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Wedbush reissued an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Friday, March 14th.

Gossamer Bio Trading Down 1.6 %

Shares of GOSS stock opened at $0.98 on Thursday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a market cap of $222.34 million, a P/E ratio of -3.06 and a beta of 1.86. The company has a 50 day moving average of $1.20 and a 200-day moving average of $1.00. Gossamer Bio, Inc. has a 12-month low of $0.50 and a 12-month high of $1.55.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). The firm had revenue of $9.38 million during the quarter, compared to analysts’ expectations of $7.02 million. Sell-side analysts anticipate that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.